# Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC

> **NCT01562210** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 28 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT01562210
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2019-05
- **Final completion:** 2020-03-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562210, "Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01562210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*